BioRegenx officer and director Sherri Adams resigns effective July 17, 2024

BIOREGENX, INC.

Sherri Adams resigned as officer and director effective July 17, 2024, to pursue other business interests.
Departure was not due to any disagreement with the company, its board, or management.
No replacement named; CEO William Resides signed the filing.
Adams' role as officer/director leaves board with at least one vacancy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sherri Adams

Officer

BRGX · BIOREGENX, INC.

Effective: 2024-07-17
Filed: July 23, 2024, 7:59 PM ET

Effective July 17, 2024, Sherri Adams resigned as an officer and director of the Company to pursue other business interests.

Departed

Sherri Adams

Director

BRGX · BIOREGENX, INC.

Effective: 2024-07-17
Filed: July 23, 2024, 7:59 PM ET

Effective July 17, 2024, Sherri Adams resigned as an officer and director of the Company to pursue other business interests.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sherri Adams resigned as Officer at BIOREGENX, INC..

Action: resigned
Role: Officer

Exact text from the filing

Effective July 17, 2024, Sherri Adams resigned as an officer and director of the Company to pursue other business interests.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sherri Adams resigned as Director at BIOREGENX, INC..

Action: resigned
Role: Director

Exact text from the filing

Effective July 17, 2024, Sherri Adams resigned as an officer and director of the Company to pursue other business interests.

View on SEC.gov

BIOREGENX, INC. filing history →

Source: SEC EDGAR

accession 0001683168-24-004996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.